Kamada Ltd. (Form 6-K Summary - Nov 2025)

This 6-K filing reports a significant clinical development milestone for Kamada Ltd.

Key Event: CYTOGAM® Trial Enrollment

• Initiative: First patient enrolled in an Investigator-Initiated Clinical Trial (IIT).
• Product: CYTOGAM®.
• Indication: Prevention of Cytomegalovirus (CMV) in kidney transplantation recipients.
• Significance: This moves CYTOGAM® toward evaluation in a new therapeutic application within the transplant space.

Note: This report primarily signals a strategic push in clinical development; no